Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $1,324.6M | $2,028.4M | $3,026.1M | $4,230.0M | $5,335.8M | $7,011.4M | $7,949.4M | $8,385.4M | $9,702.5M | $11.2B | $24.9B | $32.6B | $30.4B | $26.1B | $22.1B | $22.4B | $24.7B | $27.3B | $27.3B | $27.1B |
Discover the top 20 best undervalued stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Nov 2024, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Nov 2024.
As of today, Gilead Sciences, Inc.'s last 12-month Revenue is $28.3B, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Gilead Sciences, Inc.'s Revenue growth was 3.3%. The average annual Revenue growth rates for Gilead Sciences, Inc. have been 3.4% over the past three years, 4.8% over the past five years.
Over the last year, Gilead Sciences, Inc.'s Revenue growth was 3.3%, which is higher than industry growth of 0.1%. It indicates that Gilead Sciences, Inc.'s Revenue growth is Good.